The resolution addresses the significant public health issue of obesity in Alabama, highlighting its complex causes and the associated risks of diseases such as heart disease and diabetes. It notes that obesity incurs substantial medical costs, with the Centers for Disease Control reporting nearly $173 billion in annual expenditures nationwide, and estimates that Alabama's economy suffers a $7.2 billion impact due to obesity. The prevalence of obesity in Alabama is concerning, with 38.9% of adults and 15.6% of children enrolled in the Women, Infants, and Children program affected. The resolution also references new drug pricing models from the Centers for Medicare and Medicaid Services that could benefit Medicaid programs, particularly regarding GLP-1 medications for weight management.

In light of these factors, the resolution encourages the Alabama Medicaid Agency to explore the potential benefits of GLP-1 medications for approximately 110,000 eligible members. It calls for an assessment of potential savings from covering these medications, an evaluation of overall costs in relation to new drug pricing models, and ongoing discussions with healthcare providers and stakeholders to improve health outcomes and cost efficiency. The agency is tasked with reporting its findings to the Legislature before the 2027 Legislative Session, aiming to inform future decisions on obesity management and Medicaid coverage in Alabama.